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Abstract
Objectives To investigate the association between opium use and
subsequent risk of death.
Design Prospective cohort study.
Setting The Golestan Cohort Study in north-eastern Iran collected
detailed validated data on opium use and other exposures at baseline.
Participants were enrolled between January 2004 and June 2008 and
were followed to May 2011, with a follow-up success rate of over 99%.
Participants 50 045 participants aged 40-75 at baseline.
Main outcomes Mortality, all cause and major subcategories.
Results 17% (n=8487) of the participants reported opium use, with a
mean duration of 12.7 years. During the follow-up period 2145 deaths
were reported. The adjusted hazard ratio for all cause mortality
associated with ever use of opium was 1.86 (95% confidence interval
1.68 to 2.06). Opium consumption was significantly associated with
increased risks of deaths from several causes including circulatory
diseases (hazard ratio 1.81) and cancer (1.61). The strongest
associations were seen with deaths from asthma, tuberculosis, and
chronic obstructive pulmonary disease (11.0, 6.22, and 5.44,
respectively). After exclusion of people who self prescribed opium after
the onset of major chronic illnesses, the associations remained strong
with a dose-response relation.
Conclusion Opium users have an increased risk of death from multiple
causes compared with non-users. Increased risks were also seen in
people who used low amounts of opium for a long period and those who
had no major illness before use.
Introduction
Useofopium(lachrymapapaveris)formedicinalorrecreational
purposes has a long history in many parts of the world
1 and
continues to be common. In 2008 an estimated 13-22 million
people worldwide used opium or its derivatives as illicit drugs:
6.5-12.5 million in Asia; 3.3-3.8 million in Europe; 2.3-2.4
million in the Americas; and the rest in Africa and Oceania.
2
A small number of retrospective case-control studies or case
serieshavedescribedthepossibleroleofopiuminoesophageal
cancer,
3 4 bladder cancer,
5-7 coronary heart disease,
8-11 and a few
other select health conditions.
12-14 There is little information
from well designed prospective epidemiological studies on the
effectoftheuseofopiumonoverallorcausespecificmortality,
partly because of relatively low opium use in most established
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RESEARCHcohort studies and the difficulty of obtaining validated data.
There is also scant information on the effect of different types
of opium with respect to health outcomes.
The Golestan Cohort Study (GCS), a prospective study
established in north eastern Iran,
15 where opium consumption
isexceptionallycommon,
16hascollecteddetailedvalidateddata
on opium use from over 50 000 people.
17 This study has
collected data on typical amounts used, duration of use, and the
four major types of opiates used locally—that is, teriak, shireh,
sukhteh, and heroin. The first two can be smoked or ingested.
Sukhteh can only be ingested, and heroin can be injected,
sniffed, or smoked.
4 Using data on over 2000 deaths identified
in the initial four years of follow-up, we report the effects of
opium use, including by subtypes,
4 18 on overall and cause
specific mortality.
Methods
Study population
The Golestan Cohort Study was launched in January 2004 in
north eastern Iran after completion of a pilot study in 2003.
16 In
brief, a total of 50 045 people aged 40-75 were recruited from
January 2004 to June 2008. The cohort study was designed to
investigatethecausesofoesophagealsquamouscellcarcinoma
in Golestan province, where the risk of this cancer is extremely
high. Study participants were enrolled from those who lived in
Gonbad City and 326 villages in Golestan province, north
eastern Iran. Further details have been discussed elsewhere.
15
Assessment of exposure
Trained interviewers used a general questionnaire and a food
frequency questionnaire to collect data. The general
questionnaire included detailed queries on opium use (see
below), tobacco use, and alcohol drinking and questions on
demographic characteristics, residential history, occupation,
education, and medical history. Height, weight, and waist and
hipcircumferenceswerealsomeasured.Bloodpressureforeach
participantwasmeasuredtwicefrombotharms,with10minute
intervals, while the person was seated and relaxed. Nutritional
data were collected with a food frequency questionnaire that
was specifically designed and validated for this area.
19
Biospecimens included 10 ml of blood, 4.5 ml of midstream
urine, and hair and nail samples from each individual.
Detailed data on opium use were collected as opium use is
common in Golestan and could be a risk factor for oesophageal
cancer. Data were obtained on age of start and end of opium
use, typical amount of use in nokhod (the local unit for opium
use, equivalent to about 0.2 g), frequency of use (how many
days a week if weekly or more), and routes of administration
for the different types of opiates commonly used—namely,
teriak, sukhteh, shireh, and heroin. If participants used multiple
types of opium, or if they used opium intermittently, data were
recorded separately for each type and period of use.
Teriak,orrawopium,isdirectlyobtainedfromtheseedcapsule
oftheopiumpoppy,Papaversomniferum.
20Theripeningpoppy
capsules are incised to extract a milky juice, which turns into a
dark sticky or crumbly mass, known locally as teriak. Teriak
can be taken orally or smoked after direct heating with burning
charcoal in specialised devices such as an opium pipe. Sukhteh
is the opium dross remaining after the opium is smoked and is
taken orally. This form of opium, which is generally cheaper
than teriak, has been shown to have high mutagenic activity.
18
Shireh is a refined product of opium that is mainly obtained
from sukhteh, with or without adding teriak, boiled in water
and filtered several times to remove the insoluble materials.
18
Shireh can be ingested or smoked, by indirect heating, in a
special type of opium pipe. As indirect heating is used, the
vapour of opiate is inhaled, not its smoke. In this region users
who smoke opium generally do not mix it with any other
substances such as tobacco.
Ascertainment of cause of death
As nearly all study participants have telephones, they are
actively followed by annual telephone calls. Detailed questions
are asked regarding their health status and any admission to
hospital or outpatient procedures. All data are recorded on hard
copies as well as on a computerised database. If a study
participant is inaccessible through telephone calls, after seven
attemptsduringatwoweekperiod,researcherscontactedfriends
or local health workers. Using this method, we successfully
obtained follow-up information for over 99% of all
participants.
15 21 On learning of a reported death through the
phone calls or through the local health workers or monthly
provincial reports of death registration, a general practitioner
who is a member of the follow-up team visits the home of the
dead person and completes a validated verbal autopsy
questionnaire
21 by interviewing the closest relative of the dead
person. At the same time other members of the team gather all
available and relevant medical documents including medical
charts, radiographs, pathology reports, hospital discharge
documents, etc, from all hospitals or pathology centres, either
within the province or neighbouring provinces.
For 65% of all deaths, in addition to the verbal autopsy,
extensive medical documents—including physician notes, test
results, findings on electrocardiography and radiology,
endoscopy results, and pathology reports—were retrieved to
determinecauseofdeath.
21Fortheremainingdeaths,causewas
determined only by verbal autopsy. Our previous studies show
high accuracy (all measures of accuracy above 81%) and
reliability (κ >0.75), particularly for major groups of cause of
death, for this verbal autopsy.
21 Two separate internists
independently reviewed all collected documents, including the
verbal autopsy information and medical charts, and the cause
of death was documented with ICD-10 codes (international
classification of diseases, 10th revision). If the results were
concordant, a diagnosis was made. In case of discordance a
third, more experienced internist reviewed all documents and
the two initial diagnoses and made the final diagnosis. If a final
diagnosis could not be made for any reason, the cause of death
was coded as “unknown.”
Though cause of death should ideally be assessed by someone
blinded to the exposure data, the physician who completed the
verbalautopsybyinterviewingthenextofkinofthedeadperson
also collected some information on medical history and habits
(such as smoking and alcohol and opium use). Nevertheless,
total deaths, the main outcome of the study, could not be biased
by knowledge of the exposure. Furthermore, as the internists
whodeterminedthecauseofdeathhadnopriorbeliefregarding
the association between opium use and any specific cause of
death, except perhaps for oesophageal cancer, we believe such
information should have minimal impact on classification of
cause of death.
The major categories of death evaluated in this analysis were
the most prevalent causes of death among the participants,
including circulatory, cancer, respiratory, digestive, infectious,
external (mainly from motor vehicle crashes or other
unintentional injury and suicide), unknown, or other.
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RESEARCHStatistical analysis
After examining the proportional hazard assumption using
Schoenfeld residuals, we fitted a Cox proportional hazards
model, with age as the timescale, to estimate unadjusted and
adjusted hazard ratios and 95% confidence intervals for total
and cause specific mortality in relation to the exposures of
interest, including any opium use, type of opium used, duration
of use, cumulative use, and the method of opium consumption.
Follow-up continued until loss to follow-up, death, or 20 May
2011, whichever came first. While opium use is a potentially
important factor in all cause mortality, age is still the most
importantriskfactorfordeathandisbiologicallymoreimportant
than the time of recruitment into the cohort. Hence we chose
age as the Cox regression time variable, implying that all risk
comparisons are made between individuals of the same age. As
deaths before recruitment were not observed, participants were
leftcensoredattheageofenrolment.Wealsousedaccumulated
exposure at the time of enrolment as a fixed variable, rather
than allowing it to increment with time in the study as might
seem more natural. This was done because we had no data on
continued exposure after enrolment; we do not know how the
risk from accumulated exposure changes after cessation of
consumption; and the time within the study is typically short
comparedwiththeaccumulatedyearsofexposure.Weadjusted
for potential confounders—including sex, place of residence
(urban or rural), marital status, highest educational level,
ethnicity (Turkmen or others), and cigarette smoking—by
including indicator variables in the Cox regression models.
Further inclusion of alcohol consumption, body mass index
(BMI, either categorical or continuous), height (as a measure
of health during early adulthood), and consumption of fruit and
vegetables did not materially change the hazard ratios. As
adjustmentforacompositewealthscore(includinginformation
on ownership of car or motorbike, black and white TV, colour
TV,refrigerator,freezer,vacuumcleaner,andwashingmachine,
as well as having bath in the home) that has been previously
used to estimate socioeconomic status in Golestan Province
22
did not change the results, we have presented the main results
without adjustment for these variables. Interactions were
examinedbyincludingappropriateinteractiontermsintheCox
regression models.
For the purpose of this analysis, we defined opium users as
those who consumed opium at least once a week for at least six
months. Opium users were further classified as former users
and current users. Opium types analysed in this study were
teriak, sukhteh, shireh, and heroin. Among current users,
duration of use, which was calculated by summing the years
using any type of opium, was categorised into fifths. We then
calculated cumulative use by multiplying duration of use by
amount used. If study participants used opium intermittently
during several periods of their life, we obtained overall
cumulative use by summing cumulative use during each period
ofuse.Themethodsofopiumconsumptionwereclassifiedinto
three categories: smoking, ingestion, or both. As the number of
heroin users was small, we did not consider injection as one of
the categories of use.
Peopleofthisareamayuseopiumtoalleviatepainfromchronic
illnesses, which could lead to associations from reverse
causality. To assess this possibility, we used data collected at
enrolmenttoexcludefromanalysisanyparticipantswhostarted
opium use after experiencing ischaemic heart disease,
cerebrovascular event, hypertension, or diabetes mellitus. To
further study reverse causality, we also conducted a sensitivity
analysis by excluding deaths that occurred in the first 6, 12, 18,
and 24 months of follow-up.
Wecalculatedbothageandage-sexstandardisedmortalityrates
basedonWorldPopulation2000.Wealsocalculatedthefraction
of deaths attributed to opium use in this population using the
hazard ratios and prevalence of opium use. All statistical
analyseswereconductedwithStatastatisticalsoftware,version
11 (StataCorp, College Station, TX).
Results
Datafromall50045cohortparticipantswereusedforthisstudy,
with a total of 234 928 person years of follow-up (median 4.7
years per participant). The mean age of participants at baseline
was52.1(SD8.9)years.Mostparticipantswerewomen(58%),
74%wereTurkmen,80%livedinruralareas,88%weremarried,
83% were non-smokers, and 70% had no formal education.
Of the 17% (n=8487) of cohort members who reported ever
using opium, the mean age at enrolment was 53.4 (SD 9.2), the
mean age at which they started using opium was 39.7 (SD 9.2),
andthemeanreporteddurationofusewas12.7(SD11.1)years.
The median daily amount of opium used was 0.6 g (25th-75th
centile 0.2-1.2g). Opium users were more likely than the rest
of the cohort to be men, rural dwellers, and cigarette smokers.
The proportion of Turkmen people, married individuals, and
those with no formal education was similar to the entire cohort.
During the follow-up period until 20 May 2011, 293 (0.6%) of
the study participants, including 226 (0.5%) of those who had
never used opium and 67 (0.8%) of the opium users, were lost
tofollow-up,and2145deathswerereported,resultinginacrude
death rate of 913 per 100 000 person years. As shown in table
1⇓, an overall increased risk of death was observed for being
male, being illiterate, not being married (single, widowed,
divorced), and medical history of myocardial infarction,
cerebrovascular events, hypertension, and diabetes, whereas
ethnicity and place of residence were not associated with an
increased risk.
Inall,8660(17%)participantsreportedeversmokingcigarettes,
with an adjusted hazard ratio of 1.53 (95% confidence interval
of 1.37 to 1.70) for all causes of death. The hazard ratio for
deathassociatedwithopiumusewas1.98(1.80to2.17),before
adjustment for cigarette smoking and 1.86 (1.68 to 2.06) after
adjustment for cigarette smoking.
Table 2⇓ compares hazard ratios for overall mortality among
opiumusersstratifiedbysex,ethnicity,education,maritalstatus,
place of residence, history of chronic diseases, BMI, and
categoriesofcigarettesmoking,withtestsforinteractionacross
each group. With the exception of people with history of
cerebrovascularevents,arelativelysmallgroup,opiumusewas
associated with an increased risk of mortality among all strata.
Significantly higher increased risks of mortality were observed
among women than men (P<0.001), urban than rural dwellers
(P=0.008), obese than non-obese people (P=0.020), and those
who had never smoked than those who did (P=0.001).
Table 3⇓ shows the hazard ratios (95% confidence intervals)
for major causes of death in relation to opium use. Opium use
was associated with an increased risk of death in all major
categories, except the category classified as “external,” which
mainlyincludedunintentionalinjuriesandtrauma.Thestrongest
associations were found for infections (adjusted hazard ratio
5.47),respiratorydiseases(3.78),anddigestivediseases(3.12).
Consistent with the overall association, the hazard ratios were
higherinwomenthaninmenformostcausesofdeaths.Among
deaths from circulatory causes, opium use was associated with
anincreasedriskofischaemicheartdiseaseandcerebrovascular
events (table 3⇓). Among deaths from cancer, opium use was
associated with an increased risk of three common cancers that
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oesophageal, gastric, and lung cancers—though this was
significant only for lung cancer. Additional examination of the
association between opium use and deaths from respiratory
conditions showed that the adjusted hazard ratios were 11.0
(95% confidence interval 3.97 to 30.6) for asthma, 6.22 (2.36
to 16.4) for tuberculosis, and 5.44 (2.03 to 14.5) for chronic
obstructive pulmonary disease.
Amongst8487opiumusers,mostusedteriakonly(7308),shireh
only (721), or a combination of the two. Other forms of opium
use were far less common. Increased mortality was seen for
each subtype of opium (see table A in appendix), with the
strongestriskwithheroin,albeitwithwideconfidenceintervals.
Use of shireh (adjusted hazard ratio 2.19) was associated with
a slightly higher hazard of death than teriak (1.83), but the
difference was not significant.
To assess the dose-response relation, we classified opium users
as former users and current users. Current opium users had a
higher hazard of death than former users (table 4⇓). Among
current users, longer duration of use was not associated with a
highermortalityhazard(P=0.497fortrend).Whenweexcluded
542 people who started opium use after receiving a diagnosis
ofamajorillness(6.4%ofallopiumusers),however,wefound
adose-responseassociationwithdurationofopiumuse(P=0.001
for trend). This pattern was also seen for several major causes
of death. Assessment of the dose-response relation with
cumulativeuseyieldedsimilarresults(seetableBinappendix).
Further sensitivity analysis with exclusion of deaths that
occurred in the first 6, 12, 18, and 24 months of follow up did
not have a material effect on the point estimates (see table C in
appendix). Further adjustment did not change the results
meaningfully(seetableDinappendix),reducingthepossibility
of residual and unmeasured confounding. When we created a
“healthy group” by excluding participants with any history of
hypertension, ischemic heart disease, diabetes mellitus, or
cerebrovascular events and underweight participants and those
who had ever smoked cigarettes, the adjusted Cox hazard ratio
for opium use in relation to overall mortality was 1.90 (95%
confidence interval of 1.55 to 2.33).
Table E in the appendix shows the results by broad categories
of opium use—that is, ingestion and smoking. After exclusion
of rare methods of opium use—for instance, the four and six
participants who exclusively used heroin and sukhteh,
respectively—of the remaining individuals, 5804 only smoked
opium,2176exclusivelyingestedopium,and497reportedboth
smoking and ingestion. Both methods were associated with
increased risk of mortality: adjusted hazard ratio 2.08 for
ingestion; 1.68 for smoking; and 2.34 for both. There was a
similar pattern for most major causes of death, both before and
after adjustment for either duration of opium use or its
cumulative consumption.
Thefigure⇓presentsCoxhazardratiosinformerusersbyyears
after cessation of opium use until they were enrolled into the
study. The longer duration of cessation was associated with a
decreasing hazard ratio (P=0.003 for trend).
Basedontheoveralladjustedhazardratioforopiumuseof1.86
(1.68to2.06),andassumingthisrepresentsacausalassociation,
we calculate the fraction of deaths attributable to opium in this
population as 14.9% (12.3% to 17.5%).
Discussion
Major findings
OpiumuseiscommoninthispopulationinIranandisassociated
withanestimated86%increasedriskofdeathoverall;inwomen
the increase was 143%. This increased risk was present for
several major causes of death, including death from circulatory
disorders and cancer, for different subtypes of opium (teriak,
shireh, heroin, or combinations), for various routes of use
(smoking and ingestion), and in several study subgroups (sex,
ethnicity, residence, and others).
Evidence for causality
This large prospective study looked at opium use in relation to
overall mortality and cause specific mortality. Although causal
inferences from this study could be premature, the findings are
consistent with those from retrospective case-control studies
thathaveshownincreasedriskofoesophagealcancer,
3 4bladder
cancer,
5-7 coronary heart disease,
8 10 11 and other diseases
12-14 in
relationtoopiumuse.Also,severalofourfindingspointtoward
acausalroleforopiuminincreasingmortality.Anearlytwofold
risk of mortality in opium users is substantial and is stronger
than the estimated risk posed by tobacco use in this population.
After adjustment for several factors, including tobacco use, the
associations diminished only slightly but were still strong and
significant.
People in this region might use opium to alleviate pain from
chronic conditions, which could result in associations from
reverse causality. To avoid misleading conclusions, we carried
out a sensitivity analysis by excluding participants who started
usingselfprescribedopiumaftertheonsetoffourmajorchronic
diseases. This resulted in some attenuation of risk that was
restricted to recent users, as expected, but little change in risks
for longer term users of eight years or more. Further sensitivity
analysis excluding deaths occurring in the first 24 months of
follow-up did not make a material difference either. Finally,
longeropiumcessationwasassociatedwithlowerriskofdeath.
Opium alkaloid (such as morphine) and non-alkaloid (such as
meconic acid) constituents, and other chemicals added during
processing or generated during smoking, have a wide range of
effects and can potentially explain the diverse increased risk of
morbidityandmortalitywithopiumuse.Activationofµ-opioid
receptorsinpre-Bötzingercomplex,locatedintheventrolateral
medulla, can reduce breathing frequency, tidal volume, chest
wall compliance, and respiratory response to increased arterial
carbondioxideconcentration.
23Opiumusecanalsocauseupper
airwayconstrictionthroughinhibitionofacetylcholinerelease
23
and increased bronchial tone through provocation of histamine
release from mast cells.
11 24 Smoking opium can also cause
histological damage to the bronchi and lungs.
20 Prolonged
administrationofexogenousopioidscanhaveinhibitoryeffects
on both humoral and cell mediated immune response.
25 All of
these mechanisms could underlie the strong associations seen
with deaths from asthma, tuberculosis, and chronic obstructive
pulmonary disease. Smoking opium can expose the body to
carcinogenic polycyclic aromatic hydrocarbons, heterocyclic
aromatic hydrocarbons, and primary aromatic amines.
26 There
is a growing body of evidence indicating that opiates could act
as cancer promoters through impairing immune function,
activating angiogenesis and tumour neovascularisation,
25
increasing the concentrations of N-nitrosamines through
modifying their pharmacokinetics,
27 increasing the release of
nitric oxide,
28 or inhibiting production and release of hydrogen
peroxide.
29 Although opium use might have cardioprotective
effects in short term use,
30 it can have deleterious effects in the
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RESEARCHlong term through causing hypotension, bradycardia, and
respiratory depression that could decrease myocardial
oxygenation and hence increase the infarct size and mortality.
31
Morphine,likeotheropiatealkaloids,ismetabolisedprincipally
in the liver via conjugation with glucuronic acid.
32 Similar to
other substances metabolised by the liver, morphine can result
in hepatotoxicity.
33 Extensive animal research has shown that
morphine and morphine-like agents can increase liver enzyme
activity and lead to perivenular and focal hepatocellular
necrosis.
34-37 Chronic administration of morphine in rats is
thought to increase inflammatory infiltration and focal
parenchymal necrosis in the liver, in addition to an increase in
total lipid content of hepatocytes, all leading to lipid fibrosis
and hepatic damage.
38
Opium users in our cohort reported relatively low amounts of
use (median 0.6 g/day), considerably lower than ranges of 1-24
g reported elsewhere.
20 Although study participants might
under-report the amount used, average daily use is likely to be
lowinthisgroupasthesewerepeoplewhowereableandwilling
to participate in the study, had low rates of loss to follow-up
(<1%), and whose education, ethnic background, and marital
status was similar to non-users. Therefore, the opium users
perhaps had a lifestyle that was not substantially different from
others. These findings are in favour of a causal connection and
suggest that even relatively small amounts of opium use over
a long period can have a substantial effect on mortality.
Bothopiumingestionandopiumsmokingwereassociatedwith
an increased risk of death. Compared with ingestion, smoking
exposes individuals to more polycyclic and heterocyclic
aromatic hydrocarbons and primary aromatic amines
26 but also
exposes users to nearly 10 times less morphine. Almost 50%
of opium that is smoked adheres to the opium pipe and of the
other half that is vaporised in the pipe, a large proportion is lost
in the smoke that escapes into the surrounding air.
20
We found that opium increased the risk of death in nearly all
subgroupsofthestudyparticipants,includingmenandwomen,
Turkmen and non-Turkmen people, people who lived in urban
andruralareas,peoplewithandwithoutmajorchronicdiseases,
and smokers and non-smokers. The strength of association,
however,differedinsomesubgroupanalyses.Mostimportantly,
the hazards ratios were higher in women than in men and in
non-smokers than tobacco smokers.
Opium use is probably accurately reported in this population.
A previous pilot study nested in this population showed that
therewasastrongcorrespondencebetweenselfreportedopium
use and opium metabolites in urine, with a sensitivity and
specificity of 93% and 89%, respectively.
17 Unlike alcohol,
opium is not considered to be strictly religiously forbidden in
this area, and recreational low dose consumption is culturally
acceptable. Although there is evidence that the participants’
report of any opium use was valid, we do not know whether
their reported amount of use was also correct. In our analyses,
cumulative use of opium, estimated by multiplying duration
and amount of use, did not result in stronger associations than
duration of use alone. Therefore, responses to amount of use
could be subject to misclassification.
We used several methods to control for the effect of known and
unknown confounders. Statistical adjustment for important
potentialconfounderssuchasage,sex,placeofresidence,levels
of education, marital status, BMI, height, intake of fruit and
vegetables,acompositewealthscore,alcoholconsumption,and
cigarette smoking status had little effect on the risk estimates.
Comparedwiththosewhoneverusedopium,stratifiedanalyses
showed a consistently significant increased risk of mortality
among people who had ever used opium in almost all strata,
including in those who had ever or never smoked cigarettes.
Dose-response analyses showed a significant increasing trend
of overall and cause specific risks of mortality for increasing
doses of opium use. Finally, sensitivity analyses, through both
classic and customised methods in our study, consistently
showed the same results for the effect of opium use on risks of
mortality. Although there could still be some unmeasured
confounders or residual confounding from modelling or
measurementerrors,webelievetheirpresenceandeffectwould
notbeconsiderablebecauseofextensiveadjustmentforseveral
knownconfounders.
39 40Confoundingfactorsshouldbestrongly
associated with both the exposure and outcomes to have a
material effect,
41 and we have adequately adjusted for age,
smoking, and other confounders strongly related to both opium
use and death; other unknown factors are unlikely to be
significantlyassociatedwithbothopiumuseanddeath.Whereas
large scale randomised controlled clinical trials are the best
design to eliminate or limit residual confounding, conducting
randomised studies of opium and mortality is not ethically
feasible;thereforeprospectiveobservationalstudiesremainthe
design of choice in this setting.
Assumingacausalrelation,theimpactofopiumuseonmortality
is substantial. About 20 million people in the world use opium
or its derivatives, and these individuals are at a substantially
increased risk of death.
Strengths and limitations of the study
The strengths of this study include its prospective design, large
sample size, availability of data to adjust for confounders, prior
validationofexposureandoutcomemeasurement,andminimal
losstofollow-up.Thisstudyalsohaslimitations,whichinclude
its observational design and therefore the potential for residual
confounding and reverse causality. There is also a possibility
of outcome misclassification as the cause of death was
determined solely based on verbal autopsy in 35% of the cases.
However, we used several methods to increase the validity of
our outcome determination and to reduce the possibility of
confounding and reverse causality.
Conclusions and implications
In summary, in this large scale prospective study we found
strong increased risks of death from multiple causes in opium
users compared with non-users, even among those who used
low doses of opium. These results are consistent with results of
previous case-control studies in humans and animal studies
suggestingdeleterioushealthconsequencesofexogenousopioids
such as morphine. Further epidemiological studies on opium
use in relation to morality are needed. Also, follow-up studies
of patients taking opioid analgesics long term for treatment of
pain could shed further light on this issue.
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There is little information from well designed prospective epidemiological studies on the effect of opium use, particularly low doses over
a long period, on overall or cause specific mortality
What this study adds
Long term opium use, even in relatively low doses, is associated with an estimated 86% increased risk of death overall
Users have an increased risk for several major causes of death, including circulatory disorders and cancer
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RESEARCHTables
Table 1| Demographic and anthropometric characteristics, medical history, and habits in relation to death in participants of Golestan Cohort
Study
Relative rate SMR† No of deaths (crude rate*) No of participants (person years) Variables
Sex:
Reference 727 893 (655) 28 811 (136 279) Female
1.66 1207 1252 (1269) 21 234 (98 649) Male
Ethnicity:
Reference 972 520 (912) 12 792 (57 038) Non-Turkmen
0.99 959 1625 (914) 37 253 (177 890) Turkmen
Education (highest level):
Reference 1050 1708 (1044) 35 118 (163 647) No formal
0.67 704 316 (635) 10 708 (49 753) Up to eight years
0.44 460 89 (560) 3155 (15 883) High school
0.48 505 32 (567) 1064 (5644) University
Marital status:
Reference 924 1732 (841) 43 890 (205 921) Married
1.88 1738 22 (1519) 302 (1449) Single
1.84 1703 376 (1423) 5603 (26 422) Widow/er
1.84 1700 10 (1575) 135 (635) Divorced/other
Place of residence:
Reference 979 1625 (904) 40 012 (179 745) Rural
0.96 942 520 (942) 10 033 (55 183) Urban
History of ischaemic heart disease:
Reference 886 1797 (812) 46 994 (221 407) No
2.29 2032 348 (2574) 3051 (13 521) Yes
History of cerebrovascular event:
Reference 948 2078 (892) 49 616 (233 040) No
2.79 2646 67 (3548) 429 (1,888) Yes
Hypertension:
Reference 827 1388 (731) 40 170 (189 871) No
1.97 1627 757 (1680) 9875 (45 057) Yes
History of diabetes mellitus:
Reference 897 1836 (836) 46 591 (219 541) No
2.23 1997 309 (2008) 3454 (15 387) Yes
Cigarette smoking:
Reference 878 1537 (789) 41 385 (194 823) Never smoker
1.63 1429 608 (1516) 8660 (40 105) Ever smoker
Opium use:
Reference 818 1440 (732) 41 558 (196 825) Never user
2.02 1650 705 (1850) 8487 (38 103) Ever user
*Crude rates calculated in 10
5 person years.
†Age and sex standardised mortality rate based on 2000 world standard population.
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RESEARCHTable 2| Hazard ratios for association between opium use and mortality by subgroups in participants in Golestan Cohort Study
P for
interaction
Cox hazard ratio* (95% CI)
No (%) who ever used
opium
No (%) who never used
opium Variable Adjusted† Unadjusted
— 1.86 (1.68 to 2.06) 2.26 (2.06 to 2.47) 8487 41 558 All cohort
Sex:
<0.001 2.43 (2.05 to 2.88) 2.54 (2.16 to 2.98) 2355 (27.7) 26 456 (63.7) Women
1.63 (1.44 to 1.84) 1.82 (1.62 to 2.03) 6132 (72.3) 15 102 (36.3) Men
Ethnicity:
0.578 1.82 (1.62 to 2.05) 2.24 (2.02 to 2.48) 6552 (77.2) 30 701 (73.9) Turkmen
1.99 (1.62 to 2.45) 2.28 (1.89 to 2.76) 1935 (22.8) 10 857 (26.1) Non-Turkmen
Education:
0.558 1.89 (1.68 to 2.11) 2.24 (2.02 to 2.48) 5628 (66.3) 29 490 (71.0) Illiterate
1.76 (1.35 to 2.29) 2.23 (1.77 to 2.82) 2228 (26.3) 8480 (20.4) Up to 8 years
1.61 (0.98 to 2.67) 2.68 (1.71 to 4.18) 554 (6.50) 2601 (6.30) High school
3.65 (1.28 to 10.4) 3.90 (1.55 to 9.81) 77 (0.90) 987 (2.30) University
Marital status:
0.629 1.80 (1.61 to 2.02) 2.22 (2.00 to 2.45) 7545 (89.0) 36 345 (87.7) Married
2.36 (0.81 to 6.90) 3.22 (1.32 to 7.81) 62 (0.70) 240 (0.60) Single
2.16 (1.69 to 2.75) 2.40 (1.92 to 2.99) 843 (9.90) 4760 (11.5) Widow/er
2.10 (0.41 to 10.9) 2.22 (0.60 to 8.26) 27 (0.40) 108 (0.20) Divorced/other
Place of residence:
0.008 1.77 (1.58 to 1.99) 2.12 (1.91 to 2.35) 7485 (88.2) 32 527 (78.3) Rural
2.32 (1.85 to 2.92) 2.97 (2.43 to 3.61) 1002 (11.8) 9031 (21.7) Urban
History of ischaemic heart disease:
0.053 1.87 (1.67 to 2.09) 2.30 (2.09 to 2.54) 7784 (91.7) 39 210 (94.3) No
1.58 (1.23 to 2.04) 1.82 (1.46 to 2.28) 703 (8.30) 2348 (5.70) Yes
History of cerebrovascular event:
0.164 1.88 (1.69 to 2.08) 2.28 (2.08 to 2.50) 8379 (98.7) 41 237 (99.2) No
1.12 (0.59 to 2.13) 1.34 (0.78 to 2.33) 108 (1.30) 321 (0.80) Yes
Hypertension:
0.685 1.81 (1.59 to 2.05) 2.30 (2.06 to 2.57) 7022 (82.7) 33 148 (79.8) No
1.94 (1.63 to 2.32) 2.39 (2.04 to 2.79) 1465 (17.3) 8410 (20.2) Yes
History of diabetes mellitus:
0.320 1.87 (1.67 to 2.08) 2.33 (2.12 to 2.57) 7944 (93.6) 38 647 (93.0) No
1.67 (1.26 to 2.22) 2.00 (1.55 to 2.57) 543 (6.40) 2911 (7.00) Yes
Body mass index (BMI):
0.020 1.54 (1.12 to 2.10) 1.76 (1.32 to 2.35) 1080 (12.7) 1328 (3.20) Underweight
1.77 (1.53 to 2.06) 1.99 (1.74 to 2.28) 4344 (51.2) 13 585 (32.7) Normal weight
1.83 (1.50 to 2.23) 2.30 (1.92 to 2.75) 2088 (24.6) 14 884 (35.8) Overweight
2.25 (1.72 to 2.93) 2.93 (2.30 to 3.72) 971 (11.5) 11 753 (28.3) Obese
Cigarette smoking:
0.001 2.07 (1.83 to 2.35) 2.25 (1.99 to 2.53) 4012 (47.3) 37 373 (89.9) Never smoked
1.50 (1.27 to 1.77) 1.53 (1.30 to 1.81) 4475 (52.7) 4185 (10.1) Ever smoked
*Hazard ratio of dying in opium users in each stratum.
‡Adjusted for variables including sex, ethnicity, education level, marital status, residential place, and cigarette smoking, except if each of them is considered as
stratifying variable.
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RESEARCHTable 3| Hazard ratios for major causes of death in relation to opium use in Golestan Cohort Study
Cox hazard ratio* (95% CI)
No (%) of opium users
(n=8487, 17%) Total (n=50 045) Cause of death Women Men Total
2.43 (2.05 to 2.88) 1.63 (1.44 to 1.84) 1.86 (1.68 to 2.06) 705 (33) 2145 Any
Circulatory:
2.52 (1.98 to 3.20) 1.53 (1.28 to 1.82) 1.81 (1.56 to 2.09) 335 (31) 1073 All
2.90 (2.10 to 3.99) 1.58 (1.26 to 1.98) 1.90 (1.57 to 2.29) 208 (33) 624 Ischaemic heart disease
1.97 (1.30 to 2.97) 1.49 (1.07 to 2.08) 1.68 (1.29 to 2.18) 98 (28) 352 Cerebrovascular event
2.98 (1.35 to 6.58) 1.30 (0.71 to 2.36) 1.73 (1.06 to 2.82) 29 (30) 97 Other circulatory
Cancer:
1.42 (0.92 to 2.20) 1.70 (1.30 to 2.24) 1.61 (1.28 to 2.03) 137 (31) 449 All
2.40 (1.13 to 5.10) 1.12 (0.62 to 2.04) 1.51 (0.93 to 2.43) 30 (30) 100 Oesophagus
1.23 (0.33 to 4.65) 1.33 (0.74 to 2.40) 1.32 (0.77 to 2.26) 25 (33) 75 Stomach
1.19 (0.15 to 9.72) 2.65 (1.13 to 6.21) 2.27 (1.07 to 4.80) 18 (49) 37 Lung
1.10 (0.59 to 2.07) 2.09 (1.40 to 3.13) 1.67 (1.21 to 2.31) 64 (27) 237 Other cancer
Respiratory:
6.64 (3.30 to 13.3) 2.64 (1.50 to 4.73) 3.78 (2.36 to 6.04) 52 (55) 95 All
8.04 (2.26 to 28.6) 21.5 (2.60 to 177) 11.0 (3.97 to 30.6) 17 (74) 23 Asthma
34.1 (3.29 to 353) 3.18 (1.11 to 9.14) 5.44 (2.03 to 14.5) 17 (71) 24 COPD
4.08 (1.51 to 11.0) 1.15 (0.49 to 2.70) 1.87 (0.94 to 3.71) 18 (38) 48 Other respiratory
Digestive:
3.32 (1.24 to 8.84) 3.05 (1.60 to 5.79) 3.12 (1.82 to 5.37) 32 (46) 69 All
1.17 (0.21 to 6.40) 2.90 (1.14 to 7.34) 2.28 (1.05 to 4.97) 14 (39) 36 Liver cirrhosis
8.89 (2.20 to 35.9) 3.25 (1.34 to 7.90) 4.35 (2.01 to 9.39) 18 (55) 33 Other digestive
Infectious:
8.85 (3.51 to 22.3) 3.44 (1.54 to 7.69) 5.47 (2.87 to 10.4) 30 (59) 51 All
10.6 (2.33 to 48.7) 4.12 (1.33 to 12.7) 6.22 (2.36 to 16.4) 16 (67) 24 Tuberculosis
8.11 (2.48 to 26.5) 2.90 (0.91 to 9.23) 5.07 (2.11 to 12.2) 14 (52) 27 Other infectious
1.45 (0.58 to 3.64) 0.73 (0.44 to 1.21) 0.86 (0.54 to 1.35) 30 (22) 135 External
2.78 (1.52 to 5.06) 1.21 (0.73 to 2.02) 1.66 (1.11 to 2.48) 43 (29) 150 Other
2.03 (1.02 to 4.03) 2.66 (1.55 to 4.55) 2.42 (1.59 to 3.67) 46 (37) 123 Unknown
COPD=chronic obstructive pulmonary disease.
*Cox hazard ratios for opium use, adjusted for sex (except when stratified by sex), ethnicity, education level, marital status, residential place, and cigarette smoking
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RESEARCHTable 4| Cox hazard ratios* (95% confidence intervals) by duration of opium use in relation to all mortality and cause specific mortality
overall and after exclusion of participants who started using opium after diagnosis of serious disease (ischaemic heart disease,
cerebrovascular event, hypertension, or diabetes mellitus) in Golestan Cohort Study
P for
trend†
Fifth of duration (years) of opium use in current opium users
Current
users Formerusers
Never
users 5 (≥21 years) 4 (13-20 years) 3 (8-12 years) 2 (4-7 years) 1 (≤3 years)
All causes
— 183 122 99 107 131 642 63 1440 No of deaths
0.497 1.94 (1.64 to
2.29)
1.81 (1.49 to
2.19)
1.97 (1.59 to
2.42)
1.85 (1.51 to
2.26)
2.14 (1.79 to
2.57)
1.94 (1.75 to
2.16)
1.29 (1.00 to
1.67)
Reference Overall
0.001 1.90 (1.60 to
2.25)
1.79 (1.46 to
2.18)
2.00 (1.62 to
2.48)
1.39 (1.09 to
1.78)
1.62 (1.31 to
1.99)
1.70 (1.52 to
1.90)
1.27 (0.98 to
1.65)
Reference Before
diagnosis‡
Circulatory causes
— 72 59 50 53 63 297 38 738 No of deaths
0.490 1.55 (1.20 to
2.01)
1.79 (1.36 to
2.35)
2.05 (1.52 to
2.75)
1.87 (1.41 to
2.49)
2.09 (1.61 to
2.72)
1.84 (1.58 to
2.14)
1.57 (1.12 to
2.20)
Reference Overall
0.039 1.48 (1.13 to
1.93)
1.76 (1.32 to
2.34)
1.99 (1.47 to
2.70)
1.36 (0.95 to
1.94)
1.21 (0.86 to
1.69)
1.53 (1.30 to
1.80)
1.40 (0.98 to
1.99)
Reference Before
diagnosis‡
Cancer causes
— 47 30 17 22 13 129 8 312 No of deaths
0.003 2.26 (1.61 to
3.17)
2.01 (1.36 to
2.98)
1.52 (0.92 to
2.51)
1.71 (1.10 to
2.66)
0.96 (0.55 to
1.68)
1.73 (1.37 to
2.18)
0.77 (0.38 to
1.57)
Reference Overall
0.016 2.32 (1.65 to
3.26)
1.87 (1.23 to
2.86)
1.70 (1.05 to
2.78)
1.19 (0.68 to
2.10)
1.57 (1.00 to
2.47)
1.79 (1.41 to
2.26)
0.81 (0.39 to
1.64)
Reference Before
diagnosis‡
Respiratory causes
— 20 8 6 5 9 48 4 43 No of deaths
0.117 5.75 (3.11 to
10.6)
3.36 (1.52 to
7.46)
3.52 (1.45 to
8.56)
2.64 (1.02 to
6.83)
4.25 (2.02 to
8.93)
4.05 (2.52 to
6.52)
2.02 (0.70 to
5.84)
Reference Overall
0.078 5.51 (2.94 to
10.3)
3.56 (1.60 to
7.92)
2.98 (1.14 to
7.77)
2.42 (0.84 to
6.92)
3.75 (1.71 to
8.23)
3.85 (2.36 to
6.29)
2.01 (0.69 to
5.82)
Reference Before
diagnosis‡
Digestive causes
— 4 5 8 6 5 28 4 37 No of deaths
0.168 1.58 (0.53 to
4.67)
2.60 (0.98 to
6.88)
5.60 (2.49 to
12.6)
3.93 (1.61 to
9.60)
2.98 (1.14 to
7.75)
3.14 (1.80 to
5.47)
3.01 (1.02 to
8.85)
Reference All
0.219 1.66 (0.56 to
4.93)
2.87 (1.08 to
7.63)
6.22 (2.76 to
14.0)
3.15 (1.09 to
9.12)
3.01 (1.15 to
7.88)
3.16 (1.78 to
5.60)
3.06 (1.04 to
9.02)
Reference Before
diagnosis‡
Infectious causes
— 7 5 4 2 11 29 1 21 No of deaths
0.270 4.70 (1.80 to
12.3)
5.07 (1.81 to
14.2)
5.54 (1.81 to
16.9)
2.23 (0.50 to
9.80)
12.3 (5.69 to
26.7)
6.05 (3.17 to
11.6)
1.37 (0.18 to
10.5)
Reference Overall
0.424 3.80 (1.38 to
10.5)
4.22 (1.37 to
13.0)
7.06 (2.52 to
19.8)
2.54 (0.57 to
11.2)
8.62 (3.63 to
20.5)
5.23 (2.66 to
10.3)
1.25 (0.16 to
9.70)
Reference Before
diagnosis‡
*Adjusted for sex, ethnicity, education level, marital status, residential place, and cigarette smoking.
†P for trend calculated by assigning consecutive integers to fifths of duration of opium use in current opium users.
‡Excludes those who started opium use after diagnosis with serious disease.
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RESEARCHFigure
Hazard ratios on logarithmic scale for all cause mortality in current and former users of opium according to time since last
use, with never users as reference group (P=0.003 for trend)
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